Forget What Wall Street Says: Gold Standard Ventures Corp (GSV), Heron Therapeutics, Inc. (HRTX)

Gold Standard Ventures Corp (NYSE:GSV) recent rally took place on significantly more volume which surged nearly 328706 contracts on 30-Jan-19 versus its daily average of 187320. The first sale was made at $1.3 but later the stock became weaker, and closed with a gain of 4.62%. It was last traded at $1.36 apiece.

Gold Standard Ventures Corp (GSV): Outperform Candidate With 33.09% Upside Potential

Gold Standard Ventures Corp is maintained at an average outperform rating by 6 stock analysts, and there are at least 3.7% of shares outstanding that are currently legally short sold. The shares went up by 9.68% in value last month. Year-to-date it jumped 8.8%. Analysts are turning out to be more optimistic than before, with 6 of analysts who cover Gold Standard Ventures Corp (NYSE:GSV) advice adding it to buy candidate list. Wall Street experts also assign a $1.81 price target on Gold Standard Ventures Corp, pointing towards a 33.09% rally from current levels. The stock is trading for about -30.61% less than its 52-week high.

GSV Adds 14.29% In A Week

This company shares (GSV) so far managed to recover 25.93% since collapsing to its 52-week low. Over a week, it has seen its stock price volatility to stay at 4.73% while widening the period to a month, volatility was 4.34%. The share price has already crossed its 20 days moving average, floating at a distance of 8.58% and sits 11.11% higher versus its 50 days moving average. When looking at the past five sessions, the stock returned 14.29% gains and is down by -7.63% compared with its 200-day moving average of $1.46. Also, Gold Standard Ventures Corp (GSV) needs to overturn a -28.42% decrease it experienced over the past twelve months.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Consensus Call At 1.6

As regular trading ended, Heron Therapeutics, Inc. (HRTX) stock brought in a $1.02 rise to $26.98. The day started at a price of $26.1 but then traded as high as $27 before giving part of the gains back. As for this week, analysts appear content to stick with their bright outlook with the consensus call at 1.6. Heron Therapeutics, Inc. is given 5 buy-equivalent recommendations, 0 sells and 0 holds. The company shares sank -37.11% from their peak of $42.9 and now has a $2.05 billion market value of equity.

Heron Therapeutics, Inc. Could Grow 92.11% More

HRTX’s mean recommendation on Reuter’s scale presents no change from 1.58 thirty days ago to 1.58 now, which indicates a buy consensus from the analyst community. They see Heron Therapeutics, Inc. (HRTX) price hitting a mean target of $51.83 a share, meaning the stock still has potential that could lift the price another 92.11% . Also, the recent close suggests the stock is underpriced by 181.69% compared to the most bullish target.

Heron Therapeutics, Inc. (HRTX) Returns 4.01% This Year

The company had seen its current volume reaching at 530084 shares in the last trade. That compares with the recent volume average of 533760. At the close of regular trading, its last week’s stock price volatility was 5.23% which for the month reaches 3.64%. Heron Therapeutics, Inc. dipped to as low as $25.84 throughout the day and has returned 4.01% in this year. At one point in the past year, the shares traded as low as $19.55 but has recovered 38.01% since then.